Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast Cancer

NCT05856383 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT05856383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05856383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast Cancer
Lead sponsor
Zhejiang Cancer Hospital
Phase
Observational
Overall status
Recruiting
Start date
March 16, 2022
Completion date
December 31, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive advanced breast cancer